Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

SE Al-Batran; A Reichart; US Bankstahl; C Pauligk; TW Kraus; WO Bechstein; J Trojan; M Behrend; J Potenberg; N Homann; M Venerito; W Bohle; M Varvenne; C Bolling; DM Behringer; K Kratz-Alber; Gabriele Siegler; W Hozaeel; TO Goetze

doi:10.1200/JCO.2021.39.3_suppl.406

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

SE Al-Batran, A Reichart, US Bankstahl, C Pauligk, TW Kraus, WO Bechstein, J Trojan, M Behrend, J Potenberg, N Homann, M Venerito, W Bohle, M Varvenne, C Bolling, DM Behringer, K Kratz-Alber, Gabriele Siegler, W Hozaeel, TO Goetze

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

18 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	39
Issue number	3
DOIs	https://doi.org/10.1200/JCO.2021.39.3_suppl.406
Publication status	Published - 2021

Access to Document

10.1200/JCO.2021.39.3_suppl.406

Cite this

Al-Batran, SE., Reichart, A., Bankstahl, US., Pauligk, C., Kraus, TW., Bechstein, WO., Trojan, J., Behrend, M., Potenberg, J., Homann, N., Venerito, M., Bohle, W., Varvenne, M., Bolling, C., Behringer, DM., Kratz-Alber, K., Siegler, G., Hozaeel, W., & Goetze, TO. (2021). Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. JOURNAL OF CLINICAL ONCOLOGY , 39(3). https://doi.org/10.1200/JCO.2021.39.3_suppl.406

Al-Batran, SE ; Reichart, A ; Bankstahl, US et al. / Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. In: JOURNAL OF CLINICAL ONCOLOGY 2021 ; Vol. 39, No. 3.

@article{6420e325bd934085a9fad02f33c75d93,

title = "Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.",

author = "SE Al-Batran and A Reichart and US Bankstahl and C Pauligk and TW Kraus and WO Bechstein and J Trojan and M Behrend and J Potenberg and N Homann and M Venerito and W Bohle and M Varvenne and C Bolling and DM Behringer and K Kratz-Alber and Gabriele Siegler and W Hozaeel and TO Goetze",

year = "2021",

doi = "10.1200/JCO.2021.39.3_suppl.406",

language = "English",

volume = "39",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "3",

}

Al-Batran, SE, Reichart, A, Bankstahl, US, Pauligk, C, Kraus, TW, Bechstein, WO, Trojan, J, Behrend, M, Potenberg, J, Homann, N, Venerito, M, Bohle, W, Varvenne, M, Bolling, C, Behringer, DM, Kratz-Alber, K, Siegler, G, Hozaeel, W & Goetze, TO 2021, 'Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.', JOURNAL OF CLINICAL ONCOLOGY , vol. 39, no. 3. https://doi.org/10.1200/JCO.2021.39.3_suppl.406

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. / Al-Batran, SE; Reichart, A; Bankstahl, US et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 39, No. 3, 2021.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

AU - Al-Batran, SE

AU - Reichart, A

AU - Bankstahl, US

AU - Pauligk, C

AU - Kraus, TW

AU - Bechstein, WO

AU - Trojan, J

AU - Behrend, M

AU - Potenberg, J

AU - Homann, N

AU - Venerito, M

AU - Bohle, W

AU - Varvenne, M

AU - Bolling, C

AU - Behringer, DM

AU - Kratz-Alber, K

AU - Siegler, Gabriele

AU - Hozaeel, W

AU - Goetze, TO

PY - 2021

Y1 - 2021

U2 - 10.1200/JCO.2021.39.3_suppl.406

DO - 10.1200/JCO.2021.39.3_suppl.406

M3 - Abstract (Journal)

SN - 0732-183X

VL - 39

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 3

ER -

Al-Batran SE, Reichart A, Bankstahl US, Pauligk C, Kraus TW, Bechstein WO et al. Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial. JOURNAL OF CLINICAL ONCOLOGY . 2021;39(3). doi: 10.1200/JCO.2021.39.3_suppl.406